

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hateboer et al.

Serial No.: 10/790,562

Filed: March 1, 2004

For: RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL

Confirmation No.: 9903

Examiner: W. Schlapkohl

Group Art Unit: 1636

Attorney Docket No.: 2578-4038.3US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 24, 2006

Date

Signature

Li Feng

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Serial No.: 10/790,562

U.S. Patent Documents

U.S. Patent No.	Publication Date	<u>Patentee</u>
US - 5,631,158	05-20-1997	Dorai et al.
US - 6,475,753	11-05-2002	Ruben et al.

Other Documents

CARAVOKYRI et al., "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5," Journal of Virology, November 1995, pp. 6627-6633, Vol. 69, No. 11.

YALLOP et al., "PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins," Modern Biopharmaceuticals, ED. J. Knablein, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,

Li Feng, Ph.D.

Registration No. 57,292

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: May 24, 2006

LF/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents

Check in the amount of \$180.00

Document in ProLaw

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/790,562 INFORMATION DISCLOSURE Application Number March 1, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Hateboer et al. Group Art Unit 1636 (use as many sheets as necessary) W. Schlapkohl Examiner Name of 2578-4038.3US Sheet Attorney Docket Number

		Document Number		Name of Patentee or Applicant of		
Examiner Initials *	Cite No.1	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-5,631,158	05-20-1997	Dorai et al.		
		US- 6,475,753	11-05-2002	Ruben et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-	1	US-				
		US-			•	
		US-			-	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
Examiner Cite	Cite	Cite Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	<u>-</u>					.
			···			

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DIGGLOCUPE	Application Number	10/790,562	
INFORMATION DISCLOSURE	Filing Date	March 1, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Hateboer et al.	
	Group Art Unit	1636	
(use as many sheets as necessary)	Examiner Name	W. Schlapkohl	
Sheet 2 of 2	Attorney Docket Number	2578-4038.3US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		CARAVOKYRI et al., "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5," Journal of Virology, November 1995, pp. 6627-6633, Vol. 69, No. 11.		
		YALLOP et al., "PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins," Modern Biopharmaceuticals, ED. J. Knablein, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.		
		·		

Examiner	Date	
Signature	Considere	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.